{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:49:36Z","timestamp":1790887776747,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T00:00:00Z","timestamp":1605225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T00:00:00Z","timestamp":1605225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Helsinki including Helsinki University Central Hospital"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To investigate the characteristics of ADRs in patients admitting at the emergency room of a tertiary hospital.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We collected the patient records of 1600 emergency room visits of a university hospital in 2018. The patient files were studied retrospectively and all possible ADRs were identified and registered. Patient characteristics, drugs associated with ADRs, causality, severity, preventability, and the role of pharmacogenetics were assessed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>There were 125 cases with ADRs, resulting in a 7.8% overall incidence among emergency visits. The incidence was greatest in visits among elderly patients, reaching 14% (men) to 19% (women) in the 80\u201389\u00a0years age group. The most common causative drugs were warfarin, acetylsalicylic acid (ASA), apixaban, and docetaxel, and the most common ADRs were bleedings and neutropenia and\/or severe infections. Only two of the cases might have been prevented by pharmacogenetic testing, as advised in Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The same ATC classes, antithrombotics and cytostatics, were involved in ADRs causing university clinic hospitalizations as those identified previously in drug-related hospital fatalities. It seems difficult to prevent these events totally, as the treatments are vitally important and their risk-benefit-relationships have been considered thoroughly, and as pharmacogenetic testing could have been useful in only few cases.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00228-020-03043-3","type":"journal-article","created":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T20:02:38Z","timestamp":1605297758000},"page":"643-650","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Incidence, preventability, and causality of adverse drug reactions at a university hospital emergency department"],"prefix":"10.1007","volume":"77","author":[{"given":"Mirjam","family":"Kauppila","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janne T.","family":"Backman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikko","family":"Niemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2463-1862","authenticated-orcid":false,"given":"Outi","family":"Lapatto-Reiniluoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,13]]},"reference":[{"issue":"3","key":"3043_CR1","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/jgs.15244","volume":"66","author":"NE Morabet","year":"2018","unstructured":"Morabet NE, Uitvlugt EB, van den Bemt BJF, van den Bemt P, Janssen MJ, Karapinar-Carkit F (2018) Prevalence and preventability of drug-related hospital readmissions: a systematic review. J Am Geriatr Soc 66(3):602\u2013608","journal-title":"J Am Geriatr Soc"},{"issue":"6","key":"3043_CR2","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00228-017-2225-3","volume":"73","author":"TJ Oscanoa","year":"2017","unstructured":"Oscanoa TJ, Lizaraso F, Carvajal A (2017) Hospital admissions due to adverse drug reactions in the elderly. A meta-analysis. Eur J Clin Pharmacol 73(6):759\u2013770","journal-title":"Eur J Clin Pharmacol"},{"issue":"S10","key":"3043_CR3","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1002\/jcph.1115","volume":"58","author":"M Rieder","year":"2018","unstructured":"Rieder M (2018) Adverse drug reactions across the age continuum: epidemiology, diagnostic challenges, prevention, and treatments. J Clin Pharmacol 58(S10):S36\u2013S47","journal-title":"J Clin Pharmacol"},{"issue":"15","key":"3043_CR4","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1001\/jama.279.15.1200","volume":"279","author":"J Lazarou","year":"1998","unstructured":"Lazarou J, Pomeranz BH, Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279(15):1200\u20131205","journal-title":"JAMA"},{"issue":"11","key":"3043_CR5","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1002\/pds.3309","volume":"21","author":"A Miguel","year":"2012","unstructured":"Miguel A, Azevedo LF, Ara\u00fajo M, Pereira AC (2012) Frequency of adverse drug reactions in hospitalized patients: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf 21(11):1139\u20131154","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"3043_CR6","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1742-7843.2006.pto_264.x","volume":"98","author":"L Juntti-Patinen","year":"2006","unstructured":"Juntti-Patinen L, Kuitunen T, Pere P, Neuvonen PJ (2006) Drug-related visits to a district hospital emergency room. Basic Clin Pharmacol Toxicol 98(2):212\u2013217","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"6","key":"3043_CR7","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1445-5994.2011.02684.x","volume":"42","author":"Y Chen","year":"2012","unstructured":"Chen Y, Fan J, Hsu T, Chen M, Huang H, Cheng K et al (2012) Detection of patients presenting with adverse drug events in the emergency department. Intern Med J 42(6):651\u2013657","journal-title":"Intern Med J"},{"issue":"6","key":"3043_CR8","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.jemermed.2013.11.124","volume":"46","author":"L Roulet","year":"2014","unstructured":"Roulet L, Ballereau F, Hardouin J, Chiffoleau A, Potel G, Asseray N (2014) Adverse drug event nonrecognition in emergency departments: an exploratory study on factors related to patients and drugs. J Emerg Med 46(6):857\u2013864","journal-title":"J Emerg Med"},{"key":"3043_CR9","first-page":"2079","volume":"9","author":"TM Alhawassi","year":"2014","unstructured":"Alhawassi TM, Krass I, Bajorek BV, Pont LG (2014) A systematic review of the prevalence and risk factors for adverse drug reactions in the elderly in the acute care setting. Clin Interv Aging 9:2079\u20132086","journal-title":"Clin Interv Aging"},{"issue":"7","key":"3043_CR10","doi-asserted-by":"crossref","first-page":"e547","DOI":"10.1097\/MD.0000000000000547","volume":"94","author":"Y Chen","year":"2015","unstructured":"Chen Y, Huang H, Fan J, Chen M, Hsu T et al (2015) Comparing characteristics of adverse drug events between older and younger adults presenting to a Taiwan emergency department. Medicine 94(7):e547","journal-title":"Medicine"},{"issue":"5","key":"3043_CR11","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/gerona\/61.5.511","volume":"61","author":"JT Hanlon","year":"2006","unstructured":"Hanlon JT, Pieper CF, Hajjar ER, Sloane RJ, Lindblad CI, Ruby CM, Schmader KE (2006) Incidence and predictors of all and preventable adverse drug reactions in frail elderly persons after hospital stay. J Gerontol A Biol Sci Med Sci 61(5):511\u2013515","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"3043_CR12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/2050-6511-15-11","volume":"15","author":"AP Sun","year":"2014","unstructured":"Sun AP, Kirby B, Black C, Helms PJ, Bennie M, McLay JS (2014) Unplanned medication discontinuation as a potential pharmacovigilance signal: a nested young person cohort study. BMC Pharmacol Toxicol 15:11","journal-title":"BMC Pharmacol Toxicol"},{"issue":"9","key":"3043_CR13","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/ajhp\/59.9.841","volume":"59","author":"MB Aspinall","year":"2002","unstructured":"Aspinall MB, Whittle J, Aspinall SL, Maher RL Jr, Good CB (2002) Improving adverse-drug-reaction reporting in ambulatory care clinics at a veterans affairs hospital. Am J Health Syst Pharm 59(9):841\u2013845","journal-title":"Am J Health Syst Pharm"},{"issue":"12","key":"3043_CR14","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1001\/jama.1975.03260250028021","volume":"234","author":"FE Karch","year":"1975","unstructured":"Karch FE, Lasagna L (1975) Adverse drug reactions: a critical review. JAMA 234(12):1236\u20131241","journal-title":"JAMA"},{"issue":"2","key":"3043_CR15","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-2796.1990.tb00199.x","volume":"228","author":"J Hallas","year":"1990","unstructured":"Hallas J, Harvald B, Gram LF, Grodum E, Br\u00f8sen K, Haghfelt T et al (1990) Drug related hospital admissions: the role of definitions and intensity of data collection, and the possibility of prevention. J Intern Med 228(2):83\u201390","journal-title":"J Intern Med"},{"issue":"4","key":"3043_CR16","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1177\/1078155212465995","volume":"19","author":"LH Nazer","year":"2013","unstructured":"Nazer LH, Eljaber R, Rimawi D, Hawari FI (2013) Adverse drug events resulting in admission to the intensive care unit in oncology patients: incidence, characteristics and associated cost. J Oncol Pharm Pract 19(4):298\u2013304","journal-title":"J Oncol Pharm Pract"},{"issue":"8","key":"3043_CR17","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s00228-012-1237-2","volume":"68","author":"H L\u00f6vborg","year":"2012","unstructured":"L\u00f6vborg H, Eriksson L, J\u00f6nsson A, Bradley T, H\u00e4gg S (2012) A prospective analysis of the preventability of adverse drug reactions reported in Sweden. Eur J Clin Pharmacol 68(8):1183\u20131189","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"3043_CR18","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12874-018-0617-4","volume":"18","author":"SA Woo","year":"2018","unstructured":"Woo SA, Cragg A, Wickham ME, Peddie D, Balka E, Scheuermeyer F, Villanyi D, Hohl CM (2018) Methods for evaluating adverse drug event preventability in emergency department patients. BMC Med Res Methodol 18(1):160","journal-title":"BMC Med Res Methodol"},{"issue":"12","key":"3043_CR19","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1503\/cmaj.071594","volume":"178","author":"PJ Zed","year":"2008","unstructured":"Zed PJ, Abu-Laban R, Balen RM, Loewen PS, Hohl CM et al (2008) Incidence, severity and preventability of medication-related visits to the emergency department: a prospective study. CMAJ 178(12):1563\u20131569","journal-title":"CMAJ"},{"issue":"2","key":"3043_CR20","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/clpt.2011.287","volume":"91","author":"KR Crews","year":"2012","unstructured":"Crews KR, Gaedigk A, Dunnenberger HM, Klein TE, Shen DD, Callaghan JT, Kharasch ED, Skaar TC, Clinical Pharmacogenetics Implementation Consortium (2012) Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther 91(2):321\u2013326","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"3043_CR21","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cpt.911","volume":"103","author":"U Amstutz","year":"2018","unstructured":"Amstutz U, Henricks LM, Offer SM, Barbarino J, Schellens JHM, Swen JJ, Klein TE, McLeod HL, Caudle KE, Diasio RB, Schwab M (2018) Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther 103(2):210\u2013216","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"3043_CR22","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/clpt.2012.209","volume":"93","author":"MS Hershfield","year":"2013","unstructured":"Hershfield MS, Callaghan JT, Tassaneeyakul W, Mushiroda T, Thorn CF, Klein TE, Lee MTM (2013) Clinical Pharmacogenetics Implementation Consortium Guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin Pharmacol Ther 93(2):153\u2013158","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"3043_CR23","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/cpt.668","volume":"102","author":"J Johnson","year":"2017","unstructured":"Johnson J, Caudle K, Gong L, Whirl-Carrillo M, Stein C et al (2017) Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update. Clin Pharmacol Ther 102(3):397\u2013404","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"3043_CR24","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/cpt.147","volume":"98","author":"J Hicks","year":"2015","unstructured":"Hicks J, Bishop J, Sangkuhl K, M\u00fcller D, Ji Y, Leckband SG, Leeder JS, Graham RL, Chiulli DL, LLerena A, Skaar TC, Scott SA, Stingl JC, Klein TE, Caudle KE, Gaedigk A, Clinical Pharmacogenetics Implementation Consortium (2015) Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther 98(2):127\u2013134","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"3043_CR25","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/clpt.2013.105","volume":"94","author":"SA Scott","year":"2013","unstructured":"Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, Klein TE, Sabatine MS, Johnson JA, Shuldiner AR, Clinical Pharmacogenetics Implementation Consortium (2013) Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther 94(3):317\u2013323","journal-title":"Clin Pharmacol Ther"},{"key":"3043_CR26","doi-asserted-by":"crossref","unstructured":"Birdwell KA, Decker B, Barbarino JM, Peterson JF, Stein CM et al (2015) Clinical Pharmcogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. Clin Pharmacol Ther 98(1):19\u201324","DOI":"10.1002\/cpt.113"},{"key":"3043_CR27","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.vascn.2016.04.011","volume":"81","author":"MI Geer","year":"2016","unstructured":"Geer MI, Koul PA, Tanki SA, Shah MY (2016) Frequency, types, severity, preventability and costs of adverse drug reactions at a tertiary care hospital. J Pharmacol Toxicol Methods 81:323\u2013334","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"4","key":"3043_CR28","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/pds.1565","volume":"17","author":"C van der Hooft","year":"2008","unstructured":"van der Hooft C, Dieleman J, Siemes C, Aarnoudse A, Verhamme K et al (2008) Adverse drug reaction-related hospitalisations: a population-based cohort study. Pharmacoepidemiol Drug Saf 17(4):365\u2013371","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"14","key":"3043_CR29","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.2165\/00002018-200225140-00005","volume":"25","author":"P Olivier","year":"2002","unstructured":"Olivier P, Boulbes O, Tubery M, Lauque D, Montastruc J, Lapeyre-Mestre M (2002) Assessing the feasibility of using an adverse drug reaction preventability scale in clinical practice: a study in a French emergency department. Drug Saf 25(14):1035\u20131044","journal-title":"Drug Saf"},{"issue":"6","key":"3043_CR30","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/bcpt.12435","volume":"117","author":"O Lapatto-Reiniluoto","year":"2015","unstructured":"Lapatto-Reiniluoto O, Patinen L, Niemi M, Backman JT, Neuvonen PJ (2015) Drug-related inadvertent deaths in a university hospital \u2013 a declining trend. Basic Clin Pharmacol Toxicol 117(6):421\u2013426","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"3043_CR31","first-page":"169","volume":"238","author":"N Aldardeer","year":"2017","unstructured":"Aldardeer N, Benslimane N, Khalifa M (2017) Medications related emergency admissions: causes and recommendations. Stud Health Technol Inform 238:169\u2013172","journal-title":"Stud Health Technol Inform"},{"issue":"2","key":"3043_CR32","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3390\/pharmacy5020031","volume":"5","author":"LJ Kjeldsen","year":"2017","unstructured":"Kjeldsen LJ, Nielsen TRH, Olesen C (2017) Investigating the relative significance of drug-related problem categories. Pharmacy 5(2):31","journal-title":"Pharmacy"},{"key":"3043_CR33","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/2050-6511-14-5","volume":"14","author":"M Alves de Ara\u00fajo Lobo","year":"2013","unstructured":"Alves de Ara\u00fajo Lobo M, Pinheiro S, Castro J, Moment\u00e9 V, Pranchevicius M (2013) Adverse drug reaction monitoring: support for pharmacovigilance at a tertiary care hospital in Northern Brazil. BMC Pharmacol Toxicol 14:5","journal-title":"BMC Pharmacol Toxicol"},{"issue":"1","key":"3043_CR34","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1071\/AH12027","volume":"38","author":"AL Phillips","year":"2014","unstructured":"Phillips AL, Nigro O, Macolino KA, Scarborough KC, Doecke CJ, Angley MT, Shakib S (2014) Hospital admissions caused by adverse drug events: an Australian prospective study. Aust Health Rev 38(1):51\u201357","journal-title":"Aust Health Rev"},{"issue":"3","key":"3043_CR35","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4103\/0976-0105.160744","volume":"6","author":"A Khan","year":"2015","unstructured":"Khan A, Adil MS, Nematullah K, Ihtisham S, Aamer K, Aamir S (2015) Causality assessment of adverse drug reaction in Pulmonology Department of a Tertiary Care Hospital. J Basic Clin Pharm 6(3):84\u201388","journal-title":"J Basic Clin Pharm"},{"issue":"4","key":"3043_CR36","first-page":"276","volume":"70","author":"J Wentzell","year":"2017","unstructured":"Wentzell J, Nguyen T, Bui S, MacDonald E (2017) Pharmacy student facilitation of reporting of adverse drug reactions in a hospital. Can J Hosp Pharm 70(4):276\u2013280","journal-title":"Can J Hosp Pharm"},{"key":"3043_CR37","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3389\/fphar.2016.00358","volume":"7","author":"O Laatikainen","year":"2016","unstructured":"Laatikainen O, Sneck S, Bloigu R, Lahtinen M, Lauri T, Turpeinen M (2016) Hospitalizations due to adverse drug events in the elderly-a retrospective register study. Front Pharmacol 7:358","journal-title":"Front Pharmacol"},{"issue":"7","key":"3043_CR38","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00228-009-0641-8","volume":"65","author":"A Capuano","year":"2009","unstructured":"Capuano A, Irpino A, Gallo M, Ferrante L, Illiano ML, Rinaldi B, Filippelli A, Rossi F (2009) Regional surveillance of emergency-department visits for outpatient adverse drug events. Eur J Clin Pharmacol 65(7):721\u2013728","journal-title":"Eur J Clin Pharmacol"},{"issue":"20","key":"3043_CR39","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1001\/jama.2016.16201","volume":"316","author":"N Shehab","year":"2016","unstructured":"Shehab N, Lovegrove MC, Geller AI, Rose KO, Weidle NJ, Budnitz DS (2016) US emergency department visits for outpatient adverse drug events, 2013-2014. JAMA 316(20):2115\u20132125","journal-title":"JAMA"},{"key":"3043_CR40","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2147\/CIA.S99097","volume":"11","author":"N Parameswaran Nair","year":"2016","unstructured":"Parameswaran Nair N, Chalmers L, Peterson GM, Bereznicki BJ, Castelino RL, Bereznicki LR (2016) Hospitalization in older patients due to adverse drug reactions -the need for a prediction tool. Clin Interv Aging 11:497\u2013505","journal-title":"Clin Interv Aging"},{"issue":"3","key":"3043_CR41","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.aprim.2011.02.017","volume":"44","author":"MV Mart\u00ednez Jim\u00e9nez","year":"2012","unstructured":"Mart\u00ednez Jim\u00e9nez MV, Flores Dorado M, Espejo Guerrero J, Jim\u00e9nez Vicente P, Mart\u00ednez Mart\u00ednez F, Bernab\u00e9 Mu\u00f1oz E (2012) Pharmacotherapy negative outcomes resulting in primary care emergency visits. Aten Primaria 44(3):128\u2013135","journal-title":"Aten Primaria"},{"issue":"1","key":"3043_CR42","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4103\/0253-7613.125192","volume":"46","author":"M Belhekar","year":"2014","unstructured":"Belhekar M, Taur S, Munshi R (2014) A study of agreement between the Naranjo algorithm and WHO-UMC criteria for causality assessment of adverse drug reactions. Indian J Pharm 46(1):117\u2013120","journal-title":"Indian J Pharm"},{"issue":"3","key":"3043_CR43","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s40261-017-0601-5","volume":"38","author":"S Das","year":"2018","unstructured":"Das S, Behera S, Xavier A, Velupula S, Dkhar SA, Selvarajan S (2018) Agreement among different scales for causality assessment in drug-induced liver injury. Clin Drug Investig 38(3):211\u2013218","journal-title":"Clin Drug Investig"},{"issue":"4","key":"3043_CR44","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00228-016-2170-6","volume":"73","author":"NS Patel","year":"2017","unstructured":"Patel NS, Patel TK, Patel PB, Naik VN, Tripathi CB (2017) Hospitalizations due to preventable adverse reactions-a systematic review. Eur J Clin Pharmacol 73(4):385\u2013398","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"3043_CR45","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3390\/pharmacy6040108","volume":"6","author":"S Sundaran","year":"2018","unstructured":"Sundaran S, Udayan A, Hareendranath K, Eliyas B, Ganesan B, Hassan A, Subash R, Palakkal V, Salahudeen M (2018) Study on the classification, causality, preventability and severity of adverse drug reaction using spontaneous reporting system in hospitalized patients. Pharmacy 6(4):108","journal-title":"Pharmacy"},{"issue":"2","key":"3043_CR46","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/01.GIM.0000153664.65759.CF","volume":"7","author":"S Sanderson","year":"2005","unstructured":"Sanderson S, Emery J, Higgins J (2005) CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med 7(2):97\u2013104","journal-title":"Genet Med"},{"issue":"6","key":"3043_CR47","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1002\/jcph.1091","volume":"58","author":"JE Naschitz","year":"2018","unstructured":"Naschitz JE (2018) Escitalopram dose-dependent hyponatremia. J Clin Pharmacol 58(6):834\u2013835","journal-title":"J Clin Pharmacol"},{"key":"3043_CR48","doi-asserted-by":"crossref","unstructured":"Tsai P, Chen H, Liao S, Tseng M, Lee M (2012) Recurrent escitalopram-induced hyponatremia in an elderly woman with dementia with Lewy bodies. Gen Hosp Psychiatry 34(1):101.e5-101.e7","DOI":"10.1016\/j.genhosppsych.2011.06.007"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-020-03043-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-020-03043-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-020-03043-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T14:14:41Z","timestamp":1614953681000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-020-03043-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,13]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["3043"],"URL":"https:\/\/doi.org\/10.1007\/s00228-020-03043-3","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,13]]},"assertion":[{"value":"17 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}